Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP
  • Inequities in the global representation of sites participating in large, multicentre dialysis trials: a systematic review

    BMJ Global Health Date published:
  • Varying Association of Extended Hours Dialysis with Quality of Life

    Clinical Journal of the American Society of Nephrology Date published:
  • Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey

    BMJ Date published:
  • Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial

    Diabetology International Date published:
  • Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering

    Canadian Medical Association Journal Date published:
  • Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease

    JAMA Internal Medicine Date published:
  • P6272First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease

    European Heart Journal Date published:
  • Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program

    Journal of the American Society of Nephrology Date published:
  • Canagliflozin and Renal Outcomes in Diabetic Nephropathy

    New England Journal of Medicine Date published:
  • Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial

    Nephrology Dialysis Transplantation Date published:
  • Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

    Circulation Date published:
  • Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

    Diabetologia Date published:
  • Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease

    Annals of Internal Medicine Date published:
  • Blood pressure: at what level is treatment worthwhile?

    Australian Prescriber Date published:
  • The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study

    Diabetologia Date published:
  • Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study

    BMC Nephrology Date published: